Skip to main content
Lexeo Therapeutics, Inc. logo

Lexeo Therapeutics, Inc. — Investor Relations & Filings

Ticker · LXEO ISIN · US52886X1072 US Manufacturing
Open in API
Filings indexed 289 across all filing types
Latest filing 2026-05-11 Interim / Quarterly Rep…
Country US United States of America
Listing US LXEO

About Lexeo Therapeutics, Inc.

https://www.lexeotx.com/

Lexeo Therapeutics, Inc. is a clinical-stage genetic medicine company dedicated to developing gene therapies for genetically defined diseases. The company is advancing a diverse pipeline of investigational adeno-associated virus (AAV)-based gene therapy candidates. Its primary areas of focus are rare cardiovascular diseases and APOE4-associated Alzheimer's disease. Lexeo's strategy centers on addressing conditions with high unmet medical needs by leveraging pioneering science, including research originating from institutions such as Weill Cornell Medicine, to develop treatments with curative potential.

Recent filings

Filing Released Lang Actions
10-Q - Lexeo Therapeutics, Inc. (0001907108) (Filer)
Interim / Quarterly Report Q1 2026
2026-05-11 English
8-K - Lexeo Therapeutics, Inc. (0001907108) (Filer)
Report Publication Announcement Classification · 82% confidence The document is a short SEC Form 8-K current report (4,011 characters) that does not contain the financial statements themselves but states that the company “issued a press release” announcing quarterly results (Exhibit 99.1) and “posted…an updated corporate presentation” (Exhibit 99.2). It simply announces and attaches these materials rather than presenting the full report content. Under the “menu vs. meal” rule, this is an announcement of the publication of company reports (attached or available), which maps to “Report Publication Announcement” (RPA).
2026-05-11 English
ARS - Lexeo Therapeutics, Inc. (0001907108) (Filer)
Annual Report
2026-04-30 English
DEF 14A - Lexeo Therapeutics, Inc. (0001907108) (Filer)
Proxy Solicitation & Information Statement
2026-04-30 English
8-K - Lexeo Therapeutics, Inc. (0001907108) (Filer)
Board/Management Information Classification · 100% confidence The document is a Form 8-K filed with the SEC, dated April 28, 2026, reporting the appointment of a new director, Dr. Laura Sepp-Lorenzino, to the board of Lexeo Therapeutics, Inc. The content focuses on the change in the company's board of directors, detailing the new director's background, compensation, and related arrangements. There is no financial data or report attached; the document is an announcement of a management change. According to the filing definitions, announcements of changes in the company's board of directors or senior management fall under Board/Management Information (MANG).
2026-04-30 English
10-K - Lexeo Therapeutics, Inc. (0001907108) (Filer)
Annual Report
2026-03-30 English

Browse filings by year

5 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.